Meliha Çağla SÖNMEZER, Serhat ÜNAL, Leyla İpek RUDVAN AL

RNA-Based COVID-19 vaccine candidates with clinical phase trials in progress

Abstract: Due to the COVID-19 infection, which was recognized as a global pandemic by the WHO on March 11, 2020, the number of cases and disease-related deaths increases day by day globally. For this reason, antiviral agents used in treatment and vaccines, the most effective weapon in prevention, continue to be the most popular topic of the plan. Several situations are expected to affect the course of the pandemic. The loss of the ability of the virus to mutate and cause disease, the fact that those who become immunized by having the disease in the society reach a critical rate and create social immunity (herd immunity), and the provision of social immunity with effective vaccination can be counted as some of these situations. Candidate vaccines in the clinical phase among RNA-based vaccines: This review aimed to examine COVID-19 vaccine candidates using RNA technology and compile its current data. We used PubMed, Google Scholar, and World Health Organization (WHO) databases. Also, we followed up on the latest news and developments on vaccine companies’ websites. Conclusion: Vaccination trials, which started due to the seriousness and urgency of the situation that we are in, continue exceptionally quickly and effectively. As per the WHO›s data on July 9, 2021, there have been 291 vaccine trials, 107 of which are in the clinical phase, and 18 (16%) of the vaccine candidates in the clinical phase are RNA-based vaccines. Also, the number of RNA-based vaccines with ongoing preclinical trials is 2Key words: SARS-CoV2, COVID-19, vaccine trials, m-RNA

PDF

___

1. Sencan I, Kuzi S. The global threat of COVID-19 and evacuation of the citizens of different countries. Turkish Journal Medical Sciences 2020 April 21;50(SI-1):534-543. doi: 10.3906/sag2004-21
2. Goshua G , Pine AB , Meizlish ML, Chang CH, Zhang H et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-center, cross-sectional study. Lancet Haematology. 2020 Aug;7(8): e575-e582. doi: 10.1016/S2352- 3026(20)30216-7
3. Xie Y, You Q, Wu C, Cao S, Qu G et al. Impact of Cardiovascular Disease on Clinical Characteristics and Outcomes of Coronavirus Disease 2019 (COVID-19), Circulation Journal. 2020 July 22;84(8):1277-1283. doi: 10.1253/circj.CJ-20-0348
4. Al-Samkari H, Karp Leaf RS , Dzik WH, Carlson JCT, Fogerty AE et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020 July 23;136(4):489-500. doi: 10.1182/blood.2020006520
5. Hu K, Patel J, Swiston C, Patel BC. Ophthalmic Manifestations of Coronavirus (COVID-19). 2021 May 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 32310553.
6. Ferrarese C, Silani V, PrioriA, Galimberti S, Agostoni E et al. An Italian multicenter retrospective-prospective observational study on neurological manifestations of COVID-19. Neurological Sciences. 2020 Jun;41(6):1355-1359. doi: 10.1007/ s10072-020-04450-1
7. Pardi N, Hogan MJ, Porter FW, Weissman D, mRNA vaccines — a new vaccinology area, Nature Reviews Drug Discovery. 2018 Apr; 17(4):261-279. doi: 10.1038/nrd.2017.243
8. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A. et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults, Nature. 2020 Oct;586(7830):589-593. doi: 10.1038/ s41586-020-2639-4
9. Walsh EE, Frenck RW, Jr., Falsey AR, Kitchin N, Absalon J et al. Safety and Immunogenicity of Two RNA-Based Covid-Vaccine Candidates, New England Journal of Medicine 2020; 383:2439- 2450. doi: 10.1056/NEJMoa2027906
10. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, New England Journal of Medicine. 2020 Dec 31;383(27): 2603-2615. doi: 10.1056/NEJMoa2034577
11. Widge AT, Rouphel NG, Jackson LA, Anderson AJ, Roberts PJ et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. New England Journal of Medicine. 2021 January 7;384(1):80-82. doi: 10.1056/NEJMc2032195
12. Baden RL, El Sahly HM, Essink B , Kotloff K , Frey S et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine, New England Journal of Medicine. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389